Differentiating Malignant and Benign Lesion in Thyroid, Is There Any New Marker?

Debby Victoria Arief, Nila Kurniasari* and Ridholia

Abstract

The most common malignancy of the endocrine gland is papillary thyroid carcinoma (90% of endocrine malignancy). In many cases, the tumor showed borderline morphology between benign lesions and characteristics of papillary thyroid carcinoma. To determine malignancy, we propose new markers to assist with these difficulties and challenges. This research aims to determine the sensitivity and specificity of CD44 and CDK4 immunostaining in diagnosing papillary thyroid carcinoma. Samples of paraffin blocks with histopathology diagnosis of papillary thyroid carcinoma and components of benign thyroid follicular cells from January 2019 to December 2022 were collected. Immunohistochemical staining was done using CD44 and CDK4 antibodies. The staining in papillary thyroid carcinoma cells and benign thyroid follicular cells were compared. Conclusions: All papillary thyroid carcinoma cells expressed CD44 and CDK4 antibodies (100%), whereas 78.9% of benign thyroid follicular cells did not express CD44 and 81.57% did not express CDK4. CD44 and CDK4 could be useful in diagnosing papillary thyroid carcinoma with a sensitivity of 100% and specificity of 78.9% and 81.57% respectively.

Keywords

thyroid cancer; immunohistochemical staining; CD44; CDK4.

Cite This Article

Arief, D. V., Kurniasari, N., Ridholia. (2024). Differentiating Malignant and Benign Lesion in Thyroid, Is There Any New Marker?. International Journal of Scientific Advances (IJSCIA), Volume 5| Issue 5: Sep-Oct 2024, Pages 1008-1014, URL: https://www.ijscia.com/wp-content/uploads/2024/10/Volume5-Issue5-Sep-Oct-No.680-1008-1014.pdf

Volume 5 | Issue 5: Sep-Oct 2024